PubMed Health⌕ Search

Biomedical subjects

F Moen

Publications and source records attributed to F Moen.

4 recordsLinked to original sources

CPH-82 (Reumacon) versus auranofin (Ridaura): a 36-week study of their respective onset of action rates in RA.

The onset of action rate of CPH-82 (Reumacon), was compared with that of auranofin (AUR; Ridaura) in a 36-week randomised, double-blind, multicentre study of 60 patients with rheumatoid arthritis (RA). As compared with respective baseline values, the CPH-82 group manifested significant improvement in grip strength, Ritchie's articular index (RAI), pain ratings, and HAQ (health assessment questionnaire) scores after 8, 12, 24, and 36 weeks of treatment, with the exception of the 24-week HAQ score. The AUR group manifested corresponding improvement in RAI after 8, 12, 24, and 36 weeks. Significant differences in changes from baseline values in favour of the CPH-82 group were found for grip strength at 12 and 24 weeks, RAI score at 8 weeks, VAS score at 8 and 12 weeks, and HAQ score at 8 weeks. The findings suggest CPH-82 to manifest a more rapid onset of action than AUR. The two drugs were similar in tolerance and safety.

Adult↗

Duration of morning stiffness in rheumatic patients after medication with enteric-coated and plain naproxen tablets.

Twenty-nine adult rheumatic patients who were taking 500 mg naproxen at bedtime and had a certain degree of morning stiffness despite this medication took part in a randomized double-blind cross-over study in which the duration of morning stiffness after evening doses of 500 mg enteric-coated naproxen tablets was compared with that after identical doses of plain naproxen tablets. The duration of morning stiffness was significantly shorter after taking enteric-coated tablets (p less than 0.01), and the mean plasma naproxen morning concentration was 34% higher (p = 0.01). Since the results were unambiguous in such a small group of patients, they are judged to be of considerable clinical value.

Adult↗